Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 trial of AZD0466

Trial Profile

Phase 1 trial of AZD0466

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD-0466 (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors AstraZeneca
  • Most Recent Events

    • 26 Sep 2019 According to a Starpharma media release, the company anticipates to commence trial later this year.
    • 26 Sep 2019 According to a Starpharma media release, U.S. Food and Drug Administration (FDA) has authorised the use of AZD0466 in clinical trials under an investigational new drug (IND) application.
    • 16 Jul 2019 According to a Starpharma media release, US Food and drug administration investigational new drug application (IND) for AZD0466 is planned in the near future with the product expected to enter the clinic later this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top